Safety and Efficacy of Tigecycline in Treatment of Skin and Skin Structure Infections: Results of a Double-Blind Phase 3 Comparison Study with Vancomycin-Aztreonam

In a randomized, double-blind, controlled trial, 546 patients with complicated skin and skin structure infections received tigecycline 100 mg/day (a 100-mg initial dose and then 50 mg intravenously twice daily) or the combination of vancomycin 2 g/day (1 g intravenously twice daily) and aztreonam 4...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Breedt, Johannes, Teras, Jüri, Gardovskis, Janis, Maritz, Frans Jacobus, Vaasna, Tiit, Ross, Douglas Patrick, Gioud-Paquet, Martine, Dartois, Nathalie, Ellis-Grosse, Evelyn J., Loh, Evan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Microbiology 2005
Aiheet:
Clinical Therapeutics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC1280174/
https://ncbi.nlm.nih.gov/pubmed/16251309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.49.11.4658-4666.2005
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia